For the Inventor, By the Inventor

Enter assignee name

Montreal, Canada

Alethia Biotherapeutics Inc.

USPTO Granted Patents = 19

CIPO Patents = 3

EPO Patents = 6

Forward Citations = 105

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

Gilles Bernard Tremblay (19 out of 29 patents)

Mario Filion (19 out of 26 patents)

Roy Rabindranauth Sooknanan (9 out of 16 patents)

4. Traian Sulea (5 out of 32 patents)

5. Matthew Stuible (4 out of 5 patents)

6. Anna N Moraitis (3 out of 6 patents)

7. Elisabeth Viau (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. 9822170 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer (2017-11-21),

2. 9512211 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2016-12-06),

3. 9493562 - Anti-Siglec-15 antibodies (2016-11-15),

4. 9393302 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2016-07-19),

5. 9388242 - Nucleic acids encoding anti-Siglec-15 antibodies (2016-07-12),

6. 9067984 - Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15 (2015-06-30),

7. 9040246 - Methods of making antibodies that bind polypeptides involved in the process of bone remodeling (2015-05-26),

8. 8937163 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2015-01-20),

9. 8900579 - Siglec-15 antibodies in treating bone loss-related disease (2014-12-02),

10. 8802826 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2014-08-12),

11. 8741289 - Siglec 15 antibodies in treating bone loss-related disease (2014-06-03),

12. 8580257 - Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1) (2013-11-12),

13. 8540988 - Antibodies that bind polypeptides involved in the process of bone remodeling (2013-09-24),

14. 8444975 - Method for inhibiting bone resorption (2013-05-21),

15. 8431126 - Antibodies that bind polypeptides involved in the process of bone remodeling (2013-04-30),

Alethia Biotherapeutics Inc. is a biotechnology company focused on developing innovative therapies for oncology indications. With a primary focus on antibody-drug conjugate (ADC) technologies, Alethia aims to engineer targeted treatments that deliver potent anticancer agents directly to tumor cells while minimizing toxicity to healthy tissues. Through its cross-functional research and development efforts, the company strives to bring about breakthroughs in cancer treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#49 in Montreal

#737 in Canada

#31,713 in the World

Montreal, Canada

Alethia Biotherapeutics Inc.

Forward Citations = 105

7 inventors:

Gilles Bernard Tremblay (19 out of 29 patents)

Mario Filion (19 out of 26 patents)

Roy Rabindranauth Sooknanan (9 out of 16 patents)

4. Traian Sulea (5 out of 32 patents)

5. Matthew Stuible (4 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…